Demand and Trend Analysis of Pharmaceuticals in Africa
Study on Pharmaceuticals in Africa by Oral, Parenteral Formulations, Topical Formulations, and Inhalation Formulations from 2024 to 2034
Analysis of Pharmaceuticals Industry Covering Countries Include Analysis of Nigeria, Benin, Democratic Republic of Congo, Republic of the Congo, Ivory Coast, Sierra Leone, Rwanda, and Rest of Africa
Pharmaceutical Sales Outlook for Africa (2024 to 2034)
As per a newly published study by Fact.MR, sales of pharmaceuticals in Africa are pegged at US$ 53.19 billion in 2024. Regional demand for pharmaceuticals is forecasted to increase at 8.3% CAGR and reach a market valuation of US$ 117.79 billion by the end of 2034.
Increasing health awareness and economic growth are set to lead to rising expenditure in the healthcare sector, which will also drive an increase in the demand for pharmaceutical products. With rapid urbanization, a significant section of the population is relocating from rural areas to urban settings due to improved infrastructure, employment opportunities, and better access to several other services, including pharmaceuticals.
Noteworthy changes in lifestyles generally accompany urbanization. People’s transition to urban areas is leading to the adoption of new habits and behaviors influenced due to urban lifestyles. Increased alcohol and tobacco consumption, reduced physical activity levels, and dietary shifts to processed foods are some of the changes that are leading to several health risks, further contributing to the increased burden of numerous non-communicable diseases in the region. Pharmaceutical suppliers are responding to these trends and offering different medications to address the various healthcare requirements of people.
| Report Attributes | Details |
|---|---|
| Pharmaceutical Sales in Africa (2024E) | US$ 53.19 Billion |
| Forecasted Sales (2034F) | US$ 117.79 Billion |
| Demand Growth (2024 to 2034) | 8.3% CAGR |
| Sales in Nigeria (2024E) | US$ 4.92 Billion |
| Demand Growth in Democratic Republic of Congo (2024 to 2034) | 10.7% CAGR |
| Demand Growth in Republic of Congo (2024 to 2034) | 9.7% CAGR |
| Market Share of Oral Formulations (2034F) | 55.2% |
| Key Companies Profiled |
|
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Why are Sales of Pharmaceuticals Rising Swiftly in Africa?
“Rising Cases of Non-communicable Diseases and Supportive Initiatives for Pharmaceutical Production”
Governments from several regional countries, including Nigeria, the Democratic Republic of Congo, etc. are taking initiatives to provide easy access to certain pharmaceuticals.
For instance :
- In 2019, the UNECA (United Nations Economic Commission for Africa) was established to provide access to several essential medicines. This initiative is predicted to focus on 10 pilot countries, including Madagascar, Seychelles, Comoros, Djibouti, Rwanda, Mauritius, Eritrea, Sudan, Ethiopia, and Kenya to ensure effective healthcare facilities.
Chronic diseases, including diabetes, cardiovascular diseases, cancer, and respiratory diseases, are becoming more prevalent in African countries. Therefore, an increase in the demand for medications is experienced for the management of these conditions. Growing burden of chronic diseases is predicted to ensure the accessibility and availability of several pharmaceutical products to match the healthcare requirements of the regional population.
Country-wise Insights
What Makes Nigeria a Lucrative Market for Pharmaceutical Suppliers?
“Rising Investments in Improving Healthcare Facilities”
| Attribute | Nigeria |
|---|---|
| Market Value (2024E) | US$ 4.92 Billion |
| Growth Rate (2024 to 2034) | 7.6% CAGR |
| Projected Value (2034F) | US$ 10.20 Billion |
The government of Nigeria is taking several initiatives to improve healthcare affordability and access. These initiatives include programs to establish healthcare centers across rural areas, promote the manufacturing of pharmaceutical products locally, adoption of telemedicine services, and ensure the availability of essential medicines. The Nigerian Drug Policy, National Drug Distribution Guidelines, etc. are some programs, which are becoming popular in Nigeria.
What’s Positively Influencing Demand for Pharmaceuticals in the Democratic Republic of Congo?
“Increasing Emphasis on Improving Distribution Systems and Enhancing Local Manufacturing Capacity”
| Attribute | Democratic Republic of Congo |
|---|---|
| Market Value (2024E) | US$ 2.13 Billion |
| Growth Rate (2024 to 2034) | 10.7% CAGR |
| Projected Value (2034F) | US$ 5.87 Billion |
The Democratic Republic of Congo is concentrating on the local production of pharmaceutical products. It involves setting up several manufacturing facilities in the country to minimize dependency on pharmaceutical imports. Currently, the country is grappling with several non-communicable diseases, including diabetes and cardiovascular diseases. The rising burden of these diseases stimulates requirements for pharmaceutical products, including diagnostic tools, vaccines, and treatments.
Increasing population in the Democratic Republic of Congo and rising healthcare requirements are predicted to propel the demand for vaccines, medicines, and other pharmaceutical products. These factors are predicted to make the Democratic Republic of Congo a key market for manufacturers, who are exploring opportunities in this space.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Category-wise Insights
Which Pharmaceutical Dosage Form Accounts for Most Sales in Africa?
“High Demand for Oral Formulations Due to Their Affordability and Simplified Administration”
| Attribute | Oral Formulations |
|---|---|
| Segment Value (2024E) | US$ 25.83 Billion |
| Growth Rate (2024 to 2034) | 9.7% CAGR |
| Projected Value (2034F) | US$ 65.06 Billion |
Oral formulations, including capsules and tablets, are comparatively easy to administer. There is no need for specialized medical personnel to administer the consumption of oral medicines. In addition, they are suitable for home applications with self-administration features. Most of the patients are familiar with oral medications. Oral formulations are commonly preferred because of their convenience.
Compared to more complex forms of dosage, including inhalants or injectables, the production of oral formulations is more economical. Their affordability increases their accessibility to a larger population base in Africa. Moreover, increasing cases of chronic diseases in some African countries are predicted to have a favorable impact on the consumption of oral dosage formats.
Consumption of oral medicines effectively helps in the management of several ailments. Therefore, pharmaceutical enterprises are emphasizing the production and promotion of oral formulations.
Competition Landscape
According to the study published by Fact.MR, a market research and competitive intelligence provider, key pharmaceutical suppliers in Africa are investing to achieve certain goals, including new product development, ensuring the management of their supply chain, quality control, etc.
Key players operating in the African market are Sanofi S.A., GSK Inc., Pfizer Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Bayer AG, AstraZeneca, Hikma Pharmaceuticals PLC, Novo Nordisk A/S, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, Bristol Myers Squibb Co., Aspen Holdings, May & Baker Nigeria PLC, Johnson & Johnson, Chemiron International Limited, Neimeth International Pharmaceuticals PLC, Mopson Pharmaceutical Ltd., Pharma Deko PLC, Swiss Pharma Nigeria Limited, and Emzor Pharmaceutical Industries Limited.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Segmentation of Pharmaceutical Study in Africa
-
By Dosage Form :
- Oral Formulations
- Parenteral Formulations
- Topical Formulations
- Inhalation Formulations
-
By Distribution Channel :
- Pharmacy/OTC Stores
- Retail Stores
- Online Channels
-
By Country :
- Nigeria
- Benin
- Democratic Republic of Congo
- Republic of the Congo
- Ivory Coast
- Sierra Leone
- Rwanda
- Rest of Africa
Table of Content
1. Africa Industry - Executive Summary 1.1. Africa Industry Overview 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Fact.MR Analysis and Recommendations 2. Africa Industry Overview 2.1. Industry Coverage / Taxonomy 2.2. Industry Introduction and Definition 3. Industry Risks and Trends Assessment 3.1. Risk Assessment 3.1.1. COVID-19 Crisis and Impact 3.1.2. COVID-19 Impact Benchmark with Previous Crisis 3.1.2.1. Change in Demand 3.1.2.2. Before and After COVID-19 Crisis (Projected) 3.1.2.3. Before and After Sub-prime Crisis – 2008 (Actual) 3.1.2.4. Change in Demand Post-Recovery Period (After Each Crisis) 3.1.3. Impact on Industry and Value (US$ Mn) 3.1.3.1. Likely Loss of Value in 2023 3.1.3.2. Mid-term and Long-term Forecasts 3.1.3.3. Quarter by Quarter Demand and Recovery Assessment 3.1.4. Anticipated Demand and Value Recovery Curve 3.1.4.1. Likelihood of U-Shape Recovery 3.1.4.2. Likelihood of L-Shape Recovery 3.1.5. Recovery Period Assessment by Key Countries 3.1.6. Recovery Assessment by Key Industry Segments 3.1.7. Action Points and Recommendations for Suppliers 3.1.8. Impact on Trade Balance 3.2. Key Trends Impacting the Industry 3.3. Dosage Formulation and Source Development Trends 4. Industry Background and Data Points 4.1. Need of the Hour for Industries 4.2. Industry Wise Industry 4.0 4.3. Strategic Priorities 4.4. Life Cycle Stage 4.5. Importance of Technology 4.6. Use Cases of Pharmaceutical 4.7. Forecast Factors: Relevance and Impact 4.8. Investment Feasibility Matrix 4.9. PESTLE Analysis 4.10. Porter’s Five Forces Analysis 4.11. Industry Dynamics 4.11.1. Drivers 4.11.2. Restraints 4.11.3. Opportunity Analysis 4.11.4. Trend 5. Africa Industry Analysis 2018 to 2023 and Forecast, 2024 to 2034 5.1. Historical Industry Value (US$ Mn) Analysis, 2018 to 2023 5.2. Current and Future Industry Value (US$ Mn) Projections, 2024 to 2034 5.2.1. Y-o-Y Growth Trend Analysis 5.2.2. Absolute $ Opportunity Analysis 6. Africa Industry Analysis 2018 to 2023 and Forecast 2024 to 2034, By Dosage Form 6.1. Introduction / Key Findings 6.2. Historical Industry Value (US$ Mn) Analysis By Dosage Form, 2018 to 2023 6.3. Current and Future Industry Value (US$ Mn) Analysis and Forecast By Dosage Form, 2024 to 2034 6.3.1. Oral Formulations 6.3.2. Parenteral Formulations 6.3.3. Topical Formulations 6.3.4. Inhalation Formulations 6.4. Industry Attractiveness Analysis By Dosage Form 7. Africa Industry Analysis 2018 to 2023 and Forecast 2024 to 2034, by Distribution Channel 7.1. Introduction / Key Findings 7.2. Historical Industry Value (US$ Mn) Analysis By Distribution Channel, 2018 to 2023 7.3. Current and Future Industry Value (US$ Mn) Analysis and Forecast By Distribution Channel, 2024 to 2034 7.3.1. Pharmacy/OTC Stores 7.3.2. Retail Stores 7.3.3. Online Channels 7.4. Industry Attractiveness Analysis By Distribution Channel 8. Africa Industry Analysis 2018 to 2023 and Forecast 2024 to 2034, by Country 8.1. Introduction / Key Findings 8.2. Historical Industry Value (US$ Mn) Analysis By Country, 2018 to 2023 8.3. Current and Future Industry Value (US$ Mn) Analysis and Forecast By Country, 2024 to 2034 8.3.1. Indonesia 8.3.2. Nigeria 8.3.3. Benin 8.3.4. Democratic Republic of Congo 8.3.5. Republic of Congo 8.3.6. Ivory Coast 8.3.7. Sierra Leone 8.3.8. Rwanda 8.3.9. Rest of Africa 8.4. Industry Attractiveness Analysis By Country 9. Nigeria Industry Analysis 2018 to 2023 and Forecast 2024 to 2034 9.1. Introduction / Key Findings 9.2. Historical Industry Value (US$ Mn) Trend Analysis By Industry Taxonomy, 2018 to 2023 9.3. Industry Value (US$ Mn) Forecast By Industry Taxonomy, 2024 to 2034 9.3.1. By Dosage Form 9.3.2. By Distribution Channel 9.4. Industry Attractiveness Analysis 9.4.1. By Dosage Form 9.4.2. By Distribution Channel 10. Republic of Congo Industry Analysis 2018 to 2023 and Forecast 2024 to 2034 10.1. Introduction / Key Findings 10.2. Historical Industry Size (US$ Mn) Trend Analysis By Industry Taxonomy, 2018 to 2023 10.3. Current and Future Industry Value (US$ Mn) Analysis and Forecast, 2024 to 2034 10.3.1. By Dosage Form 10.3.2. By Distribution Channel 10.4. Industry Attractiveness Analysis 10.4.1. By Dosage Form 10.4.2. By Distribution Channel 11. Ivory Coast Industry Analysis 2018 to 2023 and Forecast 2024 to 2034 11.1. Introduction / Key Findings 11.2. Historical Industry Size (US$ Mn) Trend Analysis By Industry Taxonomy, 2018 to 2023 11.3. Current and Future Industry Value (US$ Mn) Analysis and Forecast, 2024 to 2034 11.3.1. By Dosage Form 11.3.2. By Distribution Channel 11.4. Industry Attractiveness Analysis 11.4.1. By Dosage Form 11.4.2. By Distribution Channel 12. Indonesia Industry Analysis 2018 to 2023 and Forecast 2024 to 2034 12.1. Introduction / Key Findings 12.2. Historical Industry Size (US$ Mn) Trend Analysis By Industry Taxonomy, 2018 to 2023 12.3. Current and Future Industry Value (US$ Mn) Analysis and Forecast, 2024 to 2034 12.3.1. By Dosage Form 12.3.2. By Distribution Channel 12.4. Industry Attractiveness Analysis 12.4.1. By Dosage Form 12.4.2. By Distribution Channel 13. Benin Industry Analysis 2018 to 2023 and Forecast 2024 to 2034 13.1. Introduction / Key Findings 13.2. Historical Industry Size (US$ Mn) Trend Analysis By Industry Taxonomy, 2018 to 2023 13.3. Current and Future Industry Value (US$ Mn) Analysis and Forecast, 2024 to 2034 13.3.1. By Dosage Form 13.3.2. By Distribution Channel 13.4. Industry Attractiveness Analysis 13.4.1. By Dosage Form 13.4.2. By Distribution Channel 14. Democratic Republic of Congo Industry Analysis 2018 to 2023 and Forecast 2024 to 2034 14.1. Introduction / Key Findings 14.2. Historical Industry Size (US$ Mn) Trend Analysis By Industry Taxonomy, 2018 to 2023 14.3. Current and Future Industry Value (US$ Mn) Analysis and Forecast, 2024 to 2034 14.3.1. By Dosage Form 14.3.2. By Distribution Channel 14.4. Industry Attractiveness Analysis 14.4.1. By Dosage Form 14.4.2. By Distribution Channel 15. Sierra Leone Industry Analysis 2018 to 2023 and Forecast 2024 to 2034 15.1. Introduction / Key Findings 15.2. Historical Industry Size (US$ Mn) Trend Analysis By Industry Taxonomy, 2018 to 2023 15.3. Current and Future Industry Value (US$ Mn) Analysis and Forecast, 2024 to 2034 15.3.1. By Dosage Form 15.3.2. By Distribution Channel 15.4. Industry Attractiveness Analysis 15.4.1. By Dosage Form 15.4.2. By Distribution Channel 16. Rwanda Industry Analysis 2018 to 2023 and Forecast 2024 to 2034 16.1. Introduction / Key Findings 16.2. Historical Industry Size (US$ Mn) Trend Analysis By Industry Taxonomy, 2018 to 2023 16.3. Current and Future Industry Value (US$ Mn) Analysis and Forecast, 2024 to 2034 16.3.1. By Dosage Form 16.3.2. By Distribution Channel 16.4. Industry Attractiveness Analysis 16.4.1. By Dosage Form 16.4.2. By Distribution Channel 17. Rest of Africa Industry Analysis 2018 to 2023 and Forecast 2024 to 2034 17.1. Introduction / Key Findings 17.2. Historical Industry Size (US$ Mn) Trend Analysis By Industry Taxonomy, 2018 to 2023 17.3. Current and Future Industry Value (US$ Mn) Analysis and Forecast, 2024 to 2034 17.3.1. By Dosage Form 17.3.2. By Distribution Channel 17.4. Industry Attractiveness Analysis 17.4.1. By Dosage Form 17.4.2. By Distribution Channel 18. Industry Structure Analysis 18.1. Industry Analysis by Tier of Companies 18.2. Industry Concentration 18.3. Industry Share Analysis of Top Players 18.4. Industry Presence Analysis 19. Competition Analysis 19.1. Competition Dashboard 19.2. Competition Benchmarking 19.3. Competition Deep Dive 19.3.1. GSK Inc. 19.3.1.1. Company Overview 19.3.1.2. Source overview 19.3.1.3. SWOT Analysis 19.3.1.4. Key Developments 19.3.2. Sanofi S.A. 19.3.2.1. Company Overview 19.3.2.2. Source overview 19.3.2.3. SWOT Analysis 19.3.2.4. Key Developments 19.3.3. Pfizer Inc. 19.3.3.1. Company Overview 19.3.3.2. Source overview 19.3.3.3. SWOT Analysis 19.3.3.4. Key Developments 19.3.4. Novartis AG 19.3.4.1. Company Overview 19.3.4.2. Source overview 19.3.4.3. SWOT Analysis 19.3.4.4. Key Developments 19.3.5. F. Hoffmann-La Roche Ltd. 19.3.5.1. Company Overview 19.3.5.2. Source overview 19.3.5.3. SWOT Analysis 19.3.5.4. Key Developments 19.3.6. Bayer AG 19.3.6.1. Company Overview 19.3.6.2. Source overview 19.3.6.3. SWOT Analysis 19.3.6.4. Key Developments 19.3.7. AstraZeneca 19.3.7.1. Company Overview 19.3.7.2. Source overview 19.3.7.3. SWOT Analysis 19.3.7.4. Key Developments 19.3.8. Hikma Pharmaceuticals PLC 19.3.8.1. Company Overview 19.3.8.2. Source overview 19.3.8.3. SWOT Analysis 19.3.8.4. Key Developments 19.3.9. Novo Nordisk A/S 19.3.9.1. Company Overview 19.3.9.2. Source overview 19.3.9.3. SWOT Analysis 19.3.9.4. Key Developments 19.3.10. Merck & Co., Inc. 19.3.10.1. Company Overview 19.3.10.2. Source overview 19.3.10.3. SWOT Analysis 19.3.10.4. Key Developments 19.3.11. Takeda Company Limited 19.3.11.1. Company Overview 19.3.11.2. Source overview 19.3.11.3. SWOT Analysis 19.3.11.4. Key Developments 19.3.12. Bristol Myers Squibb Co. 19.3.12.1. Company Overview 19.3.12.2. Source overview 19.3.12.3. SWOT Analysis 19.3.12.4. Key Developments 19.3.13. Aspen Holdings 19.3.13.1. Company Overview 19.3.13.2. Source overview 19.3.13.3. SWOT Analysis 19.3.13.4. Key Developments 19.3.14. May & Baker Nigeria PLC 19.3.14.1. Company Overview 19.3.14.2. Source overview 19.3.14.3. SWOT Analysis 19.3.14.4. Key Developments 19.3.15. Johnson & Johnson 19.3.15.1. Company Overview 19.3.15.2. Source overview 19.3.15.3. SWOT Analysis 19.3.15.4. Key Developments 19.3.16. Chemiron International Limited 19.3.16.1. Company Overview 19.3.16.2. Source overview 19.3.16.3. SWOT Analysis 19.3.16.4. Key Developments 19.3.17. Neimeth International Pharmaceuticals PLC 19.3.17.1. Company Overview 19.3.17.2. Source overview 19.3.17.3. SWOT Analysis 19.3.17.4. Key Developments 19.3.18. Mopson Ltd. 19.3.18.1. Company Overview 19.3.18.2. Source overview 19.3.18.3. SWOT Analysis 19.3.18.4. Key Developments 19.3.19. Pharma Deko PLC 19.3.19.1. Company Overview 19.3.19.2. Source overview 19.3.19.3. SWOT Analysis 19.3.19.4. Key Developments 19.3.20. Swiss Pharma Nigeria Limited 19.3.20.1. Company Overview 19.3.20.2. Source overview 19.3.20.3. SWOT Analysis 19.3.20.4. Key Developments 19.3.21. Emzor Industries Limited 19.3.21.1. Company Overview 19.3.21.2. Source overview 19.3.21.3. SWOT Analysis 19.3.21.4. Key Developments 20. Assumptions and Acronyms Used 21. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Africa Industry Value (US$ Mn) Analysis, by Dosage Form, 2018 to 2023
Table 02: Africa Industry Value (US$ Mn) Analysis, by Dosage Form, 2024 to 2034
Table 03: Africa Industry Value (US$ Mn) Opportunity Analysis, by Dosage Form, 2024 to 2034
Table 04: Africa Industry Value (US$ Mn) Analysis, by Distribution Channel, 2018 to 2023
Table 05: Africa Industry Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 06: Africa Industry Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 t0 2034
Table 08: Africa Industry Value (US$ Mn) Analysis, by Country, 2018 to 2023
Table 09: Africa Industry Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 10: Africa Industry Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 11: Nigeria Industry Value (US$ Mn) Analysis, by Dosage Form, 2018 to 2023
Table 12: Nigeria Industry Value (US$ Mn) Analysis, by Dosage Form, 2024 to 2034
Table 13: Nigeria Industry Value (US$ Mn) Opportunity Analysis, by Dosage Form, 2024 to 2034
Table 14: Nigeria Industry Value (US$ Mn) Analysis, by Distribution Channel, 2018 to 2023
Table 15: Nigeria Industry Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 16: Nigeria Industry Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 17: Republic of Congo Industry Value (US$ Mn) Analysis, by Dosage Form, 2018 to 2023
Table 18: Republic of Congo Industry Value (US$ Mn) Analysis, by Dosage Form, 2024 to 2034
Table 19: Republic of Congo Industry Value (US$ Mn) Opportunity Analysis, by Dosage Form, 2024 to 2034
Table 20: Republic of Congo Industry Value (US$ Mn) Analysis, by Distribution Channel, 2018 to 2023
Table 21: Republic of Congo Industry Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 22: Republic of Congo Industry Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 23: Ivory Coast Industry Value (US$ Mn) Analysis, by Dosage Form, 2018 to 2023
Table 24: Ivory Coast Industry Value (US$ Mn) Analysis, by Dosage Form, 2024 to 2034
Table 25: Ivory Coast Industry Value (US$ Mn) Opportunity Analysis, by Dosage Form, 2024 to 2034
Table 26: Ivory Coast Industry Value (US$ Mn) Analysis, by Distribution Channel, 2018 to 2023
Table 27: Ivory Coast Industry Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 29: Ivory Coast Industry Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 29: Indonesia Industry Value (US$ Mn) Analysis, by Dosage Form, 2018 to 2023
Table 30: Indonesia Industry Value (US$ Mn) Analysis, by Dosage Form, 2024 to 2034
Table 31: Indonesia Industry Value (US$ Mn) Opportunity Analysis, by Dosage Form, 2024 to 2034
Table 32: Indonesia Industry Value (US$ Mn) Analysis, by Distribution Channel, 2018 to 2023
Table 33: Indonesia Industry Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 34: Indonesia Industry Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 35: Benin Industry Value (US$ Mn) Analysis, by Dosage Form, 2018 to 2023
Table 36: Benin Industry Value (US$ Mn) Analysis, by Dosage Form, 2024 to 2034
Table 37: Benin Industry Value (US$ Mn) Opportunity Analysis, by Dosage Form, 2024 to 2034
Table 38: Benin Industry Value (US$ Mn) Analysis, by Distribution Channel, 2018 to 2023
Table 39: Benin Industry Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 40: Benin Industry Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 41: Democratic Republic of Congo Industry Value (US$ Mn) Analysis, by Dosage Form, 2018 to 2023
Table 42: Democratic Republic of Congo Industry Value (US$ Mn) Analysis, by Dosage Form, 2024 to 2034
Table 43: Democratic Republic of Congo Industry Value (US$ Mn) Opportunity Analysis, by Dosage Form, 2024 to 2034
Table 44: Democratic Republic of Congo Industry Value (US$ Mn) Analysis, by Distribution Channel, 2018 to 2023
Table 45: Democratic Republic of Congo Industry Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 46: Democratic Republic of Congo Industry Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 47: Sierra Leone Industry Value (US$ Mn) Analysis, by Dosage Form, 2018 to 2023
Table 48: Sierra Leone Industry Value (US$ Mn) Analysis, by Dosage Form, 2024 to 2034
Table 49: Sierra Leone Industry Value (US$ Mn) Opportunity Analysis, by Dosage Form, 2024 to 2034
Table 50: Sierra Leone Industry Value (US$ Mn) Analysis, by Distribution Channel, 2018 to 2023
Table 51: Sierra Leone Industry Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 52: Sierra Leone Industry Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 53: Rwanda Industry Value (US$ Mn) Analysis, by Dosage Form, 2018 to 2023
Table 54: Rwanda Industry Value (US$ Mn) Analysis, by Dosage Form, 2024 to 2034
Table 55: Rwanda Industry Value (US$ Mn) Opportunity Analysis, by Dosage Form, 2024 to 2034
Table 56: Rwanda Industry Value (US$ Mn) Analysis, by Distribution Channel, 2018 to 2023
Table 57: Rwanda Industry Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 58: Rwanda Industry Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 59: Rest of Africa Industry Value (US$ Mn) Analysis, by Dosage Form, 2018 to 2023
Table 60: Rest of Africa Industry Value (US$ Mn) Analysis, by Dosage Form, 2024 to 2034
Table 61: Rest of Africa Industry Value (US$ Mn) Opportunity Analysis, by Dosage Form, 2024 to 2034
Table 62: Rest of Africa Industry Value (US$ Mn) Analysis, by Distribution Channel, 2018 to 2023
Table 63: Rest of Africa Industry Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 64: Rest of Africa Industry Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Africa Industry Value (US$ Mn) Historical Analysis, 2018 to 2023
Figure 02: Africa Industry Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 03: Africa Industry Value Y-o-Y Growth and Forecast, 2018 to 2034
Figure 04: Africa Industry Incremental $ Opportunity, 2024 to 2034
Figure 05: Africa Industry Share and BPS Analysis by Dosage Form, 2024 & 2034
Figure 06: Africa Industry Y-o-Y Growth Projections by Dosage Form, 2024 to 2034
Figure 07: Africa Industry Attractiveness Analysis by Dosage Form, 2024 to 2034
Figure 08: Africa Industry Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 09: Africa Industry Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 10: Africa Industry Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 11: Africa Industry Share and BPS Analysis by Country, 2024 & 2034
Figure 12: Africa Industry Y-o-Y Growth Projections by Country, 2024 to 2034
Figure 13: Africa Industry Attractiveness Analysis by Country, 2024 to 2034
Figure 14: Nigeria Industry Value (US$ Mn) Historical Analysis, 2018 to 2023
Figure 15: Nigeria Industry Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 16: Nigeria Industry Value Y-o-Y Growth and Forecast, 2034
Figure 17: Nigeria Industry Incremental $ Opportunity, 2024 to 2034
Figure 18: Nigeria Industry Share and BPS Analysis by Dosage Form, 2024 & 2034
Figure 19: Nigeria Industry Y-o-Y Growth Projections by Dosage Form, 2024 to 2034
Figure 20: Nigeria Industry Attractiveness Analysis by Dosage Form, 2024 to 2034
Figure 21: Nigeria Industry Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 22: Nigeria Industry Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 23: Nigeria Industry Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 24: Republic of Congo Industry Value (US$ Mn) Historical Analysis, 2018 to 2023
Figure 25: Republic of Congo Industry Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 26: Republic of Congo Industry Value Y-o-Y Growth and Forecast, 2018 to 2034
Figure 27: Republic of Congo Industry Incremental $ Opportunity, 2024 to 2034
Figure 28: Republic of Congo Industry Share and BPS Analysis by Dosage Form, 2024 & 2034
Figure 29: Republic of Congo Industry Y-o-Y Growth Projections by Dosage Form, 2024 to 2034
Figure 30: Republic of Congo Industry Attractiveness Analysis by Dosage Form, 2024 to 2034
Figure 31: Republic of Congo Industry Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 32: Republic of Congo Industry Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 33: Republic of Congo Industry Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 34: Ivory Coast Industry Value (US$ Mn) Historical Analysis, 2018 to 2023
Figure 35: Ivory Coast Industry Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 36: Ivory Coast Industry Value Y-o-Y Growth and Forecast, 2018 to 2034
Figure 37: Ivory Coast Industry Share and BPS Analysis by Dosage Form, 2024 & 2034
Figure 38: Ivory Coast Industry Y-o-Y Growth Projections by Dosage Form, 2024 to 2034
Figure 39: Ivory Coast Industry Attractiveness Analysis by Dosage Form, 2024 to 2034
Figure 40: Ivory Coast Industry Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 41: Ivory Coast Industry Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 42: Ivory Coast Industry Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 43: Indonesia Industry Value (US$ Mn) Historical Analysis, 2018 to 2023
Figure 44: Indonesia Industry Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 45: Indonesia Industry Value Y-o-Y Growth and Forecast, 2018 to 2034
Figure 46: Indonesia Industry Share and BPS Analysis by Dosage Form, 2024 & 2034
Figure 47: Indonesia Industry Y-o-Y Growth Projections by Dosage Form, 2024 to 2034
Figure 48: Indonesia Industry Attractiveness Analysis by Dosage Form, 2024 to 2034
Figure 49: Indonesia Industry Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 50: Indonesia Industry Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 51: Indonesia Industry Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 52: Benin Industry Value (US$ Mn) Historical Analysis, 2018 to 2023
Figure 53: Benin Industry Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 54: Benin Industry Value Y-o-Y Growth and Forecast, 2018 to 2034
Figure 55: Benin Industry Share and BPS Analysis by Dosage Form, 2024 & 2034
Figure 56: Benin Industry Y-o-Y Growth Projections by Dosage Form, 2024 to 2034
Figure 57: Benin Industry Attractiveness Analysis by Dosage Form, 2024 to 2034
Figure 58: Benin Industry Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 59: Benin Industry Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 60: Benin Industry Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 61: Democratic Republic of Congo Industry Value (US$ Mn) Historical Analysis, 2018 to 2023
Figure 62: Democratic Republic of Congo Industry Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 63: Democratic Republic of Congo Industry Value Y-o-Y Growth and Forecast, 2018 to 2034
Figure 64: Democratic Republic of Congo Industry Share and BPS Analysis by Dosage Form, 2024 & 2034
Figure 65: Democratic Republic of Congo Industry Y-o-Y Growth Projections by Dosage Form, 2024 to 2034
Figure 66: Democratic Republic of Congo Industry Attractiveness Analysis by Dosage Form, 2024 to 2034
Figure 67: Democratic Republic of Congo Industry Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 68: Democratic Republic of Congo Industry Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 69: Democratic Republic of Congo Industry Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 70: Sierra Leone Industry Value (US$ Mn) Historical Analysis, 2018 to 2023
Figure 71: Sierra Leone Industry Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 72: Sierra Leone Industry Value Y-o-Y Growth and Forecast, 2018 to 2034
Figure 73: Sierra Leone Industry Share and BPS Analysis by Dosage Form, 2024 & 2034
Figure 74: Sierra Leone Industry Y-o-Y Growth Projections by Dosage Form, 2024 to 2034
Figure 75: Sierra Leone Industry Attractiveness Analysis by Dosage Form, 2024 to 2034
Figure 76: Sierra Leone Industry Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 77: Sierra Leone Industry Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 78: Sierra Leone Industry Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 79: Rwanda Industry Value (US$ Mn) Historical Analysis, 2018 to 2023
Figure 80: Rwanda Industry Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 81: Rwanda Industry Value Y-o-Y Growth and Forecast, 2018 to 2034
Figure 82: Rwanda Industry Share and BPS Analysis by Dosage Form, 2024 & 2034
Figure 83: Rwanda Industry Y-o-Y Growth Projections by Dosage Form, 2024 to 2034
Figure 84: Rwanda Industry Attractiveness Analysis by Dosage Form, 2024 to 2034
Figure 85: Rwanda Industry Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 86: Rwanda Industry Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 87: Rwanda Industry Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 88: Rest of Africa Industry Value (US$ Mn) Historical Analysis, 2018 to 2023
Figure 89: Rest of Africa Industry Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 90: Rest of Africa Industry Value Y-o-Y Growth and Forecast, 2018 to 2034
Figure 91: Rest of Africa Industry Share and BPS Analysis by Dosage Form, 2024 & 2034
Figure 92: Rest of Africa Industry Y-o-Y Growth Projections by Dosage Form, 2024 to 2034
Figure 93: Rest of Africa Industry Attractiveness Analysis by Dosage Form, 2024 to 2034
Figure 94: Rest of Africa Industry Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 95: Rest of Africa Industry Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 96: Rest of Africa Industry Attractiveness Analysis by Distribution Channel, 2024 to 2034
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What is the sales value of pharmaceuticals in Africa?
Sales of pharmaceuticals in Africa are pegged at US$ 53.19 billion in 2024.
What is the projected valuation of the African market for 2034?
Demand for pharmaceuticals in Africa is predicted to reach a market value of US$ 117.79 billion by the end of 2034.
At what rate is the demand for pharmaceuticals projected to rise in Africa?
The market in Africa is predicted to increase at a CAGR of 8.3% from 2024 to 2034.
What is the share of oral formulations in the regional market?
Oral formulations are projected to account for 55.2% share of the market in 2024.
What is the projected size of the market in Nigeria for 2024?
Sales of pharmaceuticals in Nigeria are estimated at US$ 4.92 billion in 2024.
At what CAGR is the demand for pharmaceuticals predicted to rise in the Democratic Republic of Congo?
Sales of pharmaceuticals in the Democratic Republic of Congo are projected to increase at 10.7% CAGR from 2024 to 2034.
Demand and Trend Analysis of Pharmaceuticals in Africa